Medical Education Library

Examining Alternative Topical Therapy for Atopic Dermatitis


A supplement to Skin and Allergy News and supported by SkinMedica.
This supplement is based on a faculty clinical roundtable discussion held September 29, 2007, in San Francisco, California.

Topic Highlights

Table of Contents
Faculty/Faculty Disclosure

To view the supplement, click the image above.

Table of Contents

• Epidemiology and Pathogenesis

• Treatment Goals and Approaches

• Core Therapy

• Microbial Colonization and Infection

• Adherence Issues

• Topical Steroids: Choices and Issues

• HPA-Axis Suppression

• A New Steroid Option

• Incorporating New Therapy Into Practice

• Summary Comments and Observations

Faculty/Faculty Disclosure

Lawrence F. Eichenfield, MD
Professor of Pediatrics and Medicine (Dermatology)
University of California, San Diego
Chief of Pediatric and Adolescent Dermatology
Rady Children's Hospital
San Diego, California
Dr. Eichenfield has disclosed that he is an investigator for and has received research grants and support from Hill Dermaceuticals, Inc., Novartis Pharmaceuticals Corporation, and Stiefel Laboratories, Inc. He also is a consultant to and on the advisory board of Astellas Pharma Inc., Graceway Pharmaceuticals, LLC, Novartis, Stiefel, and SkinMedica, Inc.

Robert G. Greenberg, MD
Private Practice
Director, East Bay Psoriasis Treatment Center
San Ramon, California
Dr. Greenberg has disclosed that he is a consultant to and on the speaker's bureau for Abbott Laboratories, Amgen Inc., CollaGenex Pharmaceuticals Inc., Dermik Laboratories, Galderma Laboratories, L.P., Genentech, Inc., Medicis Pharmaceutical Corporation, SkinMedica, Stiefel, and Warner Chilcott.

Leon H. Kircik, MD
Associate Clinical Professor of Dermatology
Indiana University Medical Center
Medical Director
DermResearch, PLLC
Louisville, Kentucky
Dr. Kircik has disclosed that he has received research support from, is consultant to, and is on the speaker's bureau for 3M Laboratories, Abbott, Acambis, Allergan Inc., Amgen, Astellas, Bayer HealthCare Pharmaceuticals, Biogen-Idec, Biolife, LLC, Breckenridge Pharmaceutical, Inc., Centocor, Inc., CollaGenex, CombiMatrix, Coria Laboratories, Ltd., Dermik, The Dow Chemical Company, Ferndale Laboratories, Inc., Galderma, Genentech, GlaxoSmithKline, Healthpoint, Ltd., Intendis, Medicis, Merck Serono, NanoBio Corporation, Novartis, NUCRYST Pharmaceuticals Corp., OrthoNeutrogena, QLT Inc., Quatrix, SkinMedica, Stiefel, ToleRx, Inc., Valeant Pharmaceuticals International, and Warner-Chilcott.

Amy S. Paller, MD
Walter J. Hamlin Professor and Chair
Department of Dermatology
Northwestern University
Feinberg School of Medicine
Chicago, Illinois
Dr. Paller has disclosed that she is a consultant to Astellas, Novartis, SkinMedica, and Stiefel.

Rebecca L. Smith, MD
Fort Mill Dermatology, LLC
Fort Mill, South Carolina
Dr. Smith has disclosed that she is a consultant to Coria, SkinMedica, and Stiefel.

Copyright © 2007 Elsevier Inc.

Next Article: